Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunvozertinib + Chemotherapy in EGFRm+ NSCLC After EGFR-TKI Failure
NCT06195189Phase 2Recruiting
- Sponsor
- Sichuan University
- Start
- Feb 2024
- Primary completion
- Dec 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of sunvozertinib in non-small cell lung cancer (NSCLC), sponsored by Sichuan University. Started Feb 2024; status: recruiting.
02
Drugs
sunvozertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06195189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06195189.